HC Wainwright Issues Negative Outlook for ALGS Earnings

Aligos Therapeutics, Inc. (NASDAQ:ALGS) – Research analysts at HC Wainwright reduced their Q2 2026 earnings per share estimates for Aligos Therapeutics in a report released on Tuesday, May 12th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings of ($0.75) per share for the quarter, down from their previous forecast of ($0.22). HC Wainwright has a “Buy” rating and a $50.00 price target on the stock. The consensus estimate for Aligos Therapeutics’ current full-year earnings is ($6.95) per share. HC Wainwright also issued estimates for Aligos Therapeutics’ Q3 2026 earnings at ($3.16) EPS, Q4 2026 earnings at ($2.22) EPS, FY2026 earnings at ($8.42) EPS, Q1 2027 earnings at ($1.03) EPS, Q2 2027 earnings at ($1.04) EPS, Q3 2027 earnings at ($1.06) EPS, Q4 2027 earnings at ($0.44) EPS, FY2027 earnings at ($3.56) EPS, FY2028 earnings at ($2.69) EPS, FY2029 earnings at ($2.28) EPS and FY2030 earnings at ($0.82) EPS.

Aligos Therapeutics (NASDAQ:ALGS) last released its quarterly earnings data on Thursday, May 7th. The company reported ($2.21) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.29) by $0.08. The company had revenue of $2.83 million for the quarter, compared to the consensus estimate of $0.25 million. Aligos Therapeutics had a negative return on equity of 139.47% and a negative net margin of 1,919.68%.

Other research analysts also recently issued reports about the company. Westpark Capital began coverage on Aligos Therapeutics in a report on Thursday, March 26th. They issued a “buy” rating and a $48.00 target price on the stock. Jefferies Financial Group raised Aligos Therapeutics to a “strong-buy” rating in a report on Thursday, March 26th. Wall Street Zen downgraded Aligos Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, May 9th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aligos Therapeutics in a report on Monday, April 20th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Aligos Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $41.50.

Aligos Therapeutics Price Performance

Shares of ALGS opened at $6.67 on Thursday. The company has a market capitalization of $41.29 million, a P/E ratio of -0.77 and a beta of 2.28. Aligos Therapeutics has a one year low of $5.12 and a one year high of $13.69. The business’s 50 day simple moving average is $7.05 and its 200-day simple moving average is $8.06.

Institutional Trading of Aligos Therapeutics

A number of large investors have recently made changes to their positions in ALGS. Woodline Partners LP bought a new stake in shares of Aligos Therapeutics in the 1st quarter valued at $2,602,000. Geode Capital Management LLC increased its holdings in Aligos Therapeutics by 21.3% during the 2nd quarter. Geode Capital Management LLC now owns 34,048 shares of the company’s stock worth $246,000 after purchasing an additional 5,978 shares in the last quarter. XTX Topco Ltd bought a new position in Aligos Therapeutics during the 2nd quarter worth about $100,000. NorthCrest Asset Manangement LLC bought a new position in Aligos Therapeutics during the 3rd quarter worth about $98,000. Finally, Vanguard Group Inc. increased its holdings in Aligos Therapeutics by 22.8% during the 3rd quarter. Vanguard Group Inc. now owns 171,689 shares of the company’s stock worth $1,683,000 after purchasing an additional 31,913 shares in the last quarter. Institutional investors own 60.43% of the company’s stock.

More Aligos Therapeutics News

Here are the key news stories impacting Aligos Therapeutics this week:

• Positive Sentiment: Aligos announced ten abstracts accepted for poster presentations at EASL 2026, showcasing multiple pipeline programs in hepatitis B, HDV, and MASH and potentially increasing investor confidence in its clinical development progress. Article Title
• Neutral Sentiment: HC Wainwright reiterated a Buy rating and $50 price target, but adjusted multiple earnings estimates for 2026-2030, reflecting continued belief in the stock’s long-term potential despite near-term losses.
• Neutral Sentiment: The firm lowered estimates for several quarters and fiscal years, including Q2 2026, Q3 2026, Q4 2026, Q2 2027, Q3 2027, Q4 2027, FY2026, FY2027, FY2028, FY2029, and FY2030, which mainly signals updated modeling rather than a change in the investment thesis.
• Negative Sentiment: Some of the revised estimates were weaker than before, suggesting the path to profitability may be more challenging in the near term and could limit upside if execution does not improve.

About Aligos Therapeutics

Aligos Therapeutics, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small‐molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections.

Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners.